Henri Huttunen - Herantis Pharma Chief Scientific Officer
| HRTIS Stock | EUR 1.49 0.07 4.49% |
Executive
Dr. Henri J. Huttunen, Ph.D. serves as Chief Scientific Officer at Herantis Pharma Oyj. He cofounded Herantis Pharma Oyj in 2008 and served as the Companys founding CEO until February 2010. He also served as member of the Board of Directors of the Company until April 2014. Dr. Huttunen has previously held research positions at the University of Helsinki, Orion Pharma, and Massachusetts General Hospital, Harvard Medical School . Dr. Huttunen also leads an academic research group focusing in molecular mechanisms of Alzheimers disease at the Neuroscience Center, University of Helsinki
| Professional Marks | Ph.D |
| Phone | 358 9222 1195 |
| Web | https://www.herantis.com |
Herantis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.6005) % which means that it has lost $0.6005 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (13.3662) %, meaning that it generated substantial loss on money invested by shareholders. Herantis Pharma's management efficiency ratios could be used to measure how well Herantis Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | EXECUTIVE Age | ||
| John Lapvetelainen | Sampo Oyj A | 57 | |
| Lasse Luukkainen | Kesko Oyj | 40 | |
| Juha Makela | UPM Kymmene Oyj | 61 | |
Management Performance
| Return On Equity | -13.37 | |||
| Return On Asset | -0.6 |
Herantis Pharma Oyj Leadership Team
Elected by the shareholders, the Herantis Pharma's board of directors comprises two types of representatives: Herantis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Herantis. The board's role is to monitor Herantis Pharma's management team and ensure that shareholders' interests are well served. Herantis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Herantis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henri Huttunen, Chief Scientific Officer | ||
| Sigrid Booms, Director of Clinical Development | ||
| Antti D, CEO COO | ||
| Jutta Poutanen, Chief Pharmaceutical Officer | ||
| Jani Koskinen, Project Manager | ||
| Outi MD, Chief Ofcer | ||
| Tone Kvale, Chief Officer |
Herantis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Herantis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.37 | |||
| Return On Asset | -0.6 | |||
| Current Valuation | 25.86 M | |||
| Shares Outstanding | 16.91 M | |||
| Shares Owned By Insiders | 31.52 % | |||
| Shares Owned By Institutions | 32.60 % | |||
| Price To Earning | (7.20) X | |||
| Price To Book | 15.17 X | |||
| Gross Profit | 90 K | |||
| EBITDA | (9.74 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Herantis Stock
Herantis Pharma financial ratios help investors to determine whether Herantis Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Herantis with respect to the benefits of owning Herantis Pharma security.